Twist Bioscience’s (TWST) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Twist Bioscience (NASDAQ:TWST) in a research note issued to investors on Friday morning,Weiss Ratings reports.

Other analysts also recently issued reports about the company. Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Barclays decreased their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Finally, Evercore ISI decreased their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.56.

Twist Bioscience Stock Up 7.2%

Shares of TWST opened at $34.11 on Friday. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average price of $28.43 and a 200-day moving average price of $32.09. The firm has a market capitalization of $2.06 billion, a P/E ratio of -23.52 and a beta of 2.38. Twist Bioscience has a 12-month low of $24.07 and a 12-month high of $55.33.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 31,348 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the transaction, the chief executive officer owned 601,212 shares in the company, valued at $19,353,014.28. This represents a 4.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Paula Green sold 9,724 shares of the company’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $313,015.56. Following the transaction, the senior vice president owned 114,678 shares in the company, valued at approximately $3,691,484.82. This trade represents a 7.82% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,368 shares of company stock valued at $2,036,204. 3.01% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently modified their holdings of TWST. GAMMA Investing LLC increased its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after acquiring an additional 303 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after acquiring an additional 302 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Twist Bioscience during the second quarter valued at about $97,000. CWM LLC increased its holdings in shares of Twist Bioscience by 61.4% during the third quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after acquiring an additional 1,648 shares in the last quarter. Finally, Bayforest Capital Ltd increased its holdings in shares of Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after acquiring an additional 1,604 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.